期刊
REVIEWS ON RECENT CLINICAL TRIALS
卷 5, 期 1, 页码 14-27出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157488710790820544
关键词
GBM; glioblastoma; temozolomide; molecular therapy; radiation; MGMT
资金
- NIH [7R01CA108633-05, 1RC2CA148190-01]
- Brain Tu-mor Funders Collaborative
- American College of Radiology
- NATIONAL CANCER INSTITUTE [R01CA108633, RC2CA148190] Funding Source: NIH RePORTER
Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal adult primary brain tumor. Median survival rates range from 12-15 months. The current standard of care for GBM has evolved from resection followed by adjuvant radiotherapy to resection, concurrent adjuvant chemotherapy (temozolomide) and radiation, and additional adjuvant chemotherapy. The expression of specific molecular biomarkers, especially O-6 -methylguanine methyltransferase (MGMT) status, may determine the response of the tumor to treatment, and helps in identifying the magnitude of benefit from this regimen. By identifying further biological subtypes of GBM at the molecular level, specific targeted therapies could be developed and used in the future for more individualized therapeutic regimens. This article will review the current therapies for GBM and the investigation of new molecular and targeted therapies, such as EGFR inhibitors, mTOR/PI3Kinase inhibitors, and anti-angiogenesis agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据